New strategy identified for overcoming resistance to KRAS-targeted cancer therapies

Vishnu Kumarasamy, PhD, first author, Research Assistant Professor of Oncology, Department of Molecular & Cellular BiologyThe FDA approval of the RAS inhibitor daraxonrasib marks an important advance in cancer treatment, but acquired resistance remains a major challenge. Our findings show that sustained cell cycle represents a common vulnerability that can be therapeutically exploited to overcome resistance and improve treatment durability."

Source:

Roswell Park Comprehensive Cancer Center

Journal reference: